title: Cilostazol: an antiplatelet agent for the neurointerventionist?
abstract: Antiplatelet agents are essential for the successful management of patients undergoing a variety of neurointerventional procedures. The most commonly used anti-platelet agents are aspirin, clopidogrel and prasugrel. However, there exist an alternative class of anti-platelet agent that may prove useful for neurointerventionists. In particular a drug called cilostazol may have numerous added advantages above and beyond its antiplatelet effect that may be valuable for our patients. In this short review we aim to highlight some of these potential advantages.
authors.affiliation: Department of Neuroradiology, The Karolinska University Hospital, Stockholm, Sweden.
authors.forename: P
authors.initials: P
authors.lastname: Bhogal
authors.affiliation: Department of Neuroradiology, The Karolinska University Hospital, Stockholm, Sweden.
authors.forename: P A
authors.initials: PA
authors.lastname: Brouwer
authors.affiliation: Department of Interventional Neuroradiology, The Royal London Hospital, London, UK.
authors.forename: H L D
authors.initials: HL
authors.lastname: Makalanda
mesh_terms: D000077407:Cilostazol; D006801:Humans; D019635:Neurosurgical Procedures / Q000009:adverse effects*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011183:Postoperative Complications / Q000209:etiology / Q000517:prevention & control*; D015607:Stents / Q000009:adverse effects; D013777:Tetrazoles / Q000627:therapeutic use*
chemical_list: D010975:Platelet Aggregation Inhibitors; D013777:Tetrazoles; D000077407:Cilostazol
keywords: Atherosclerosis; Intervention; Plaque; Platelets; Subarachnoid